Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
received:
24
08
2023
accepted:
17
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.
Identifiants
pubmed: 39465249
doi: 10.1038/s41541-024-00999-6
pii: 10.1038/s41541-024-00999-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
201Informations de copyright
© 2024. The Author(s).
Références
Laracy, J. C., Kamboj, M. & Vardhana, S. A. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. Curr. Opin. Infect. Dis. 35, 271–279 (2022).
doi: 10.1097/QCO.0000000000000841
pubmed: 35849516
pmcid: 9922441
Vijenthira, A. et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136, 2881–2892 (2020).
doi: 10.1182/blood.2020008824
pubmed: 33113551
pmcid: 7746126
Becerril-Gaitan, A. et al. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur. J. Cancer 160, 243–260 (2022).
doi: 10.1016/j.ejca.2021.10.014
pubmed: 34794855
Choi, B. et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 383, 2291–2293 (2020).
doi: 10.1056/NEJMc2031364
pubmed: 33176080
Aydillo, T. et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N. Engl. J. Med. 383, 2586–2588 (2020).
doi: 10.1056/NEJMc2031670
pubmed: 33259154
Lee, C. Y. et al. Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. Cancer Discov. 12, 62–73 (2022).
doi: 10.1158/2159-8290.CD-21-1033
pubmed: 34753749
Borges, V. et al. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma. mSphere 6, e0024421 (2021).
doi: 10.1128/mSphere.00244-21
pubmed: 34319130
Choudhary, M. C., Crain, C. R., Qiu, X., Hanage, W. & Li, J. Z. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 74, 237–245 (2022).
doi: 10.1093/cid/ciab380
Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277–282 (2021).
doi: 10.1038/s41586-021-03291-y
pubmed: 33545711
pmcid: 7610568
Azeem, M. I. et al. Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood Cancer Discov. 4, 106–117 (2023).
doi: 10.1158/2643-3230.BCD-22-0173
pubmed: 36511813
Li, F. F. et al. A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG. J. Clin. Virol. 146, 105050 (2022).
doi: 10.1016/j.jcv.2021.105050
pubmed: 34883405
Chang, A. et al. Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. Cancer Res Commun. 2, 1684–1692 (2022).
doi: 10.1158/2767-9764.CRC-22-0471
pubmed: 36644323
pmcid: 9833496
Nooka, A. K. et al. Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. J. Clin. Oncol. 40, 3057–3064 (2022).
doi: 10.1200/JCO.21.02257
pubmed: 35259002
pmcid: 9462534
Reynolds, C. J. et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 377, eabq1841 (2022).
doi: 10.1126/science.abq1841
pubmed: 35699621
Aleman, A. et al. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma. EBioMedicine 98, 104886 (2023).
doi: 10.1016/j.ebiom.2023.104886
pubmed: 37995467
pmcid: 10708991
Wagner, A. et al. Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants. Vaccines 12, https://doi.org/10.3390/vaccines12050518 (2024).
Branagan, A. R. et al. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Adv. 5, 1535–1539 (2021).
doi: 10.1182/bloodadvances.2020003880
pubmed: 33683337
pmcid: 7948269
Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N. Engl. J. Med. 388, 183–185 (2023).
doi: 10.1056/NEJMc2214293
pubmed: 36546661
Edara, V. V. et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 29, 516–521 e513 (2021).
doi: 10.1016/j.chom.2021.03.009
pubmed: 33798491
pmcid: 7980225
Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841–848 e843 (2020).
doi: 10.1016/j.chom.2020.04.004
pubmed: 32289263
pmcid: 7153529
Edara, V. V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep. Med. 3, 100529 (2022).
doi: 10.1016/j.xcrm.2022.100529
pubmed: 35233550
pmcid: 8784612
Edara, V. V. et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N. Engl. J. Med. 385, 664–666 (2021).
doi: 10.1056/NEJMc2107799
pubmed: 34233096
Vanderheiden, A. et al. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. Curr. Protoc. Immunol. 131, e116 (2020).
doi: 10.1002/cpim.116
pubmed: 33215858
pmcid: 7864545
Katzelnick, L. C. et al. Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. PLoS Negl. Trop. Dis. 12, e0006862 (2018).
doi: 10.1371/journal.pntd.0006862
pubmed: 30356267
pmcid: 6226209